Latest Breaking News On - Shabir hasham - Page 3 : comparemela.com

Santhera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed

Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting

United statesSwitzerland generalUnited kingdomEric hoffmanEva kaliasShabir hashamReveragen biopharmaEuropean medicines agencySanthera pharmaceuticals holdingDrug administrationRegulatory agencyNational institutes of healthUs department of defenseReveragen biopharma incDuchenne research fundHead investor relations communications

Santhera Pharmaceuticals Holding AG: Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, March 2, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory

Switzerland generalUnited statesUnited kingdomDennis riedlShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthDuchenne research fundFoundation to eradicate duchenneDrug administrationRegulatory agency

Investegate |Santhera Pharmaceuticals Holdi Announcements | Santhera Pharmaceuticals Holdi: European Medicines Agency Validates Santhera s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Investegate announcements from Santhera Pharmaceuticals Holdi, European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Switzerland generalUnited statesUnited kingdomShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceMuscular dystrophy association united statesSanthera pharmaceuticals holdingHead investor relations communicationsEuropean unionCommittee for medicinal products human useSanthera pharmaceuticalsNational institutes of healthDrug administration

Santhera Pharmaceuticals Holding AG: European Medicines Agency Validates Santhera s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, October 31, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone

Switzerland generalUnited statesUnited kingdomShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthEuropean commissionDuchenne research fundFoundation to eradicate duchenneDrug administrationSanthera pharmaceuticals holding

Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update

Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesUnited kingdomShabir hashamAndrew smithEva kaliasDario eklundLife science allianceSanthera pharmaceuticalsEuropean commissionDrug administrationSanthera pharmaceuticals holdingRaxone to chiesi groupInternational conference on children bone healthEuropean unionEuropean medicines agency